Publicacions en què col·labora amb MARÍA DE LOS ÁNGELES GOICOECHEA DIEZHANDINO (50)

2024

  1. Renin–angiotensin–aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial

    Hipertensión y riesgo vascular, Vol. 41, Núm. 2, pp. 95-103

  2. Tubular biomarkers and histology in lupus nephritis

    International Journal of Rheumatic Diseases, Vol. 27, Núm. 6

  3. Tubular biomarkers in proteinuric kidney disease: histology correlation and kidney prognosis of tubular biomarkers

    Clinical Kidney Journal, Vol. 17, Núm. 5

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Obesity, chronic kidney disease progression and the role of the adipokine C1q/TNF related protein-3

    Nefrologia, Vol. 43, Núm. 3, pp. 328-334

2021

  1. A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?

    Kidney International

  2. Obesity related risk for chronic kidney disease progression and cardiovascular disease after propensity score matching

    Hipertension y Riesgo Vascular, Vol. 38, Núm. 2, pp. 63-71

  3. Renal long-term outcome of critically ill COVID-19 patients with acute kidney failure and continuous renal replacement therapy

    Clinical Kidney Journal

  4. Riesgo relacionado con la obesidad para la progresión de insuficiencia renal crónica y enfermedad cardiovascular tras emparejamiento por puntaje de propensión

    Hipertensión y riesgo vascular, Vol. 38, Núm. 2, pp. 63-71

  5. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

  6. Use of renin–angiotensin–aldosterone system blockade in controversial chronic kidney disease populations

    Medicina Clinica, Vol. 156, Núm. 11, pp. 561-567

2020

  1. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

    Kidney International

  2. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists

    Nefrologia, Vol. 40, Núm. 1, pp. 66-74

  3. Progresión de la enfermedad renal crónica en pacientes con hipertensión resistente sometidos a 2 estrategias terapéuticas: intensificación con diuréticos de asa vs. antagonistas de la aldosterona

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 40, Núm. 1, pp. 65-73

  4. The effect of renin–angiotensin–aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design

    Hipertensión y riesgo vascular, Vol. 37, Núm. 3, pp. 101-107

2019

  1. An old disease, a new diagnosis; A 49 year-old man with nephrotic syndrome

    Journal of Nephropathology, Vol. 8, Núm. 3

  2. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 2, pp. 128-139

  3. Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1

    Clinical Kidney Journal, Vol. 12, Núm. 3, pp. 420-426

  4. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial

    Journal of Nephrology, Vol. 32, Núm. 4, pp. 581-587

2018

  1. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study)

    Cardiovascular Drugs and Therapy, Vol. 32, Núm. 3, pp. 255-263